Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants

Completed

Conditions: Healthy Volunteers
Narcolepsy Type 1

Interventions: Device: Portable EEG Device
Device: Portable ECG Device
Device: Accelerometry

First Posted Date: 2020-06-24

Last Posted Date: 2021-05-07

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT04445129

Locations: 🇺🇸
Research Carolina Elite, LLC, Denver, North Carolina, United States
🇺🇸
Delta Waves Sleep Disorders and Research Center, Colorado Springs, Colorado, United States
🇺🇸
Intrepid Research, Cincinnati, Ohio, United States

and more 10 locations

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-788

First Posted Date: 2020-06-22

Last Posted Date: 2021-09-05

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT04441255

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Neoplasms

Interventions: Drug: Dazostinag
Drug: Pembrolizumab
Drug: Platinum
Drug: 5-fluorouracil

First Posted Date: 2020-06-09

Last Posted Date: 2024-12-20

Lead Sponsor: Takeda

Target Recruit Count: 374

Registration Number: NCT04420884

Locations: 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 64 locations

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Biological: TAK-102

First Posted Date: 2020-05-28

Last Posted Date: 2024-07-31

Lead Sponsor: Takeda

Target Recruit Count: 11

Registration Number: NCT04405778

Locations: 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Withdrawn

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: TAK-573
Drug: Bortezomib
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2020-05-19

Last Posted Date: 2020-07-14

Lead Sponsor: Takeda

Registration Number: NCT04392648

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: TAK-981
Drug: Pembrolizumab

First Posted Date: 2020-05-11

Last Posted Date: 2024-03-22

Lead Sponsor: Takeda

Target Recruit Count: 49

Registration Number: NCT04381650

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of California Irvine Medical Center, Orange, California, United States

and more 49 locations

ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice

Withdrawn

Conditions: Crohn Disease

First Posted Date: 2020-04-16

Last Posted Date: 2020-10-06

Lead Sponsor: Takeda

Registration Number: NCT04349449

Locations: 🇨🇦
Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada
🇨🇦
REGIONAL HEALTH AUTHORITY B doing business as HORIZON HEALTH NETWORK, Fredericton, New Brunswick, Canada
🇨🇦
Nova ScotiaHealth Authority, Halifax, Nova Scotia, Canada

and more 11 locations

A Study of TAK-071 in People With Parkinson Disease

Phase 2

Completed

Conditions: Parkinson Disease
Healthy Participants

Interventions: Drug: TAK-071
Drug: Placebo

First Posted Date: 2020-04-06

Last Posted Date: 2024-05-14

Lead Sponsor: Takeda

Target Recruit Count: 64

Registration Number: NCT04334317

Locations: 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Augusta University, Augusta, Georgia, United States

and more 18 locations

A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting

Conditions: Multiple Myeloma
Neoplasms, Plasma Cell

First Posted Date: 2020-03-31

Last Posted Date: 2024-07-03

Lead Sponsor: Takeda

Target Recruit Count: 482

Registration Number: NCT04328662

Locations: 🇨🇳
Beijing Chao-yang Hospital,Capital Medical University(Shijingshan), Beijing, Beijing, China
🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳
Beijing Chao-yang Hospital,Capital Medical University, Beijing, Beijing, China

and more 25 locations

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: 9vHPV Vaccine
Biological: Dengue Tetravalent Vaccine (TDV)

First Posted Date: 2020-03-18

Last Posted Date: 2024-02-07

Lead Sponsor: Takeda

Target Recruit Count: 614

Registration Number: NCT04313244

Locations: 🇹🇭
Siriraj Hospital, Bangkoknoi, Khet Bangkok Noi, Thailand
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭
The Hospital for Tropical Diseases, Bangkok, Thailand

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy